Introduction {#S0001}
============

Schizophrenia is a common multifactorial psychiatric disorder.[@CIT0001] It is a complex disease caused by the interaction of environmental and genetic factors. Early twin studies showed that the heritability of schizophrenia can reach 80%.[@CIT0002] Although the evidence that genetic factors play a significant role in schizophrenia is continuing to accumulate, their exact mechanistic involvement in this disease remains unclear. It has been hypothesized that many neurotransmitters are involved in the etiology of schizophrenia, including dopamine,[@CIT0003] serotonin,[@CIT0004] and glutamate.[@CIT0005]

Galanin (GAL) is a 30-amino-acid neuropeptide widely distributed in the central nervous system and associated with many physiological activities and diseases of the nervous system, such as arousal/sleep, pain perception, learning, and memory, as well as inflammation, depression, Alzheimer's disease, epilepsy, and schizophrenia.[@CIT0006],[@CIT0007] It works mainly through three receptor subtypes, galanin receptor 1 (GalR1), GalR2, and GalR3, which belong to the family of G-protein-coupled receptors. GalR1 works through G~i~/G~o~ on adenylate cyclase to reduce cAMP, inhibit K^+^ outflows, and make the cell membrane hyperpolarized.[@CIT0008] Functionally, galanin is known to inhibit neuronal firing and the release of norepinephrine, serotonin (5-HT), dopamine, as well as glutamate and acetylcholine.[@CIT0009]--[@CIT0011] GalR1 is mainly distributed in the hypothalamus, locus coeruleus (LC), amygdala, and other cortical regions.[@CIT0008] It is encoded by the *GALR1* gene, which is located at 18p23 in humans and has a length of 27,091 bp, containing three exons. A large number of reports have shown that GalR1 is closely related to many mental health conditions, such as depression, addiction, and Alzheimer's disease. In addition, an association between galanin and major depressive disorder has been reported in the Han Chinese population.[@CIT0012] Studies have confirmed that galanin plays a role in promoting depression through GalR1, while GalR2 plays an anti-depressive role. Polymorphisms of the *GALR1, GALR2*, and *GALR3* genes are highly correlated with depression, suggesting that new antidepressants that act on GalR1--3 could be developed.[@CIT0013] GalR1 has also been reported to be related to Alzheimer's disease, as well as heroin and opioid addiction. Rat experiments have also shown that GalR1 in LC is a target for the treatment of addiction.[@CIT0014],[@CIT0015] Moreover, rs5371 of *GALR1* has been shown to be associated with stress and addiction in African-Americans.[@CIT0016]

Although GalR1 is clearly closely related to mental health conditions, to the best of our knowledge no study has been performed on the association between the *GALR1* gene and schizophrenia. This work explores the relationship between the *GALR1* gene's 5′ regulatory sequence and schizophrenia through a case--control study.

Materials and Methods {#S0002}
=====================

Study Subjects {#S0002-S2001}
--------------

This study examined the blood samples of 636 subjects of Han ethnicity in northern China, including 289 patients in the schizophrenia group (132 males and 157 females) and 347 patients in the control group (186 males and 161 females). The mean age of the patients was 45.4 ± 8.1 (mean ± standard deviation) years, and the mean age of the healthy subjects was 44.6 ± 13.9 years. The mean age of disease onset in the case group was 34.5 ± 7.12. The disease duration was 5--23 years. All included patients were paranoid schizophrenics. All patients were assessed for age at first hospitalization, first-degree relatives with a history of mental illness, alcohol or drug abuse, reactions to antipsychotic medicine for schizophrenia, suicide attempts, and anticholinergic medication. Only patients who fully met the criteria for schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-4) were included in this study, as diagnosed by psychiatrists. The inclusion criteria for the case group were as follows: (1) Han ethnicity from northern China; (2) recruited from the Third People's Hospital of Liaoning Province; and (3) fully meeting the requirements of DSM-4 standard. The inclusion criteria for the control group were as follows: (1) Han ethnicity from northern China; (2) recruited from healthy adult blood donors; and (3) no history of mental illness in at least three generations of their family. If the participants suffered from any other mental illnesses or serious physiological diseases, or were relatives of the other participants, they were excluded. Each of the subjects provided written informed consent before participating in this study. This study was conducted in accordance with the Helsinki Declaration. Sample collection and analysis were approved by the Ethics Committee of China Medical University.

DNA Extraction {#S0002-S2002}
--------------

Peripheral blood samples collected from each subject were stored in EP tubes, and genomic DNA was extracted by the phenol-chloroform method.[@CIT0017] The concentration and purity of the DNA were determined using a UV spectrophotometer.

Segment Selection and Primer Design {#S0002-S2003}
-----------------------------------

To detect polymorphisms that could potentially affect expression of the *GALR1* gene, we selected the 5′ regulatory region of the *GALR1* gene and focused on a 1545 bp (−1367 bp to +177 bp, ATG is +1) fragment containing part of it. As this part of the 5′ regulatory region is closest to the coding region, polymorphism within this fragment is more likely to affect gene expression. Primers were designed using Primer Premier 5 ([[www.premierbiosoft.com](http://www.premierbiosoft.com)]{.ul}). The primers used in PCR were as follows: F 5′-ACGTGACTGGCCCTGCTATACC-3′, R 5′-CGCCAGCACGGTGATCACTAG-3′.

Polymerase Chain Reaction Amplification {#S0002-S2004}
---------------------------------------

Polymerase chain reaction (PCR) was performed on a Thermal Cycler Dice™ (TP650) (Japan). The amplification system included 0.2 μL of 5 U/μL LA enzyme (Takara, Japan), 10 μL of 2×GC Buffer I, 2 μL of dNTP, 1.5 μL of 5 pmol/μL primers, and 2 μL of 50 ng/μL DNA template; sterilized deionized water was also added to a total volume of 20 μL. PCR reaction conditions were as follows: pre-denaturation at 94°C for 5 min; followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 62.5°C for 30 s, and extension at 72°C for 30 s; and finally extension at 72°C for 7 min.

Sequencing and Alignment {#S0002-S2005}
------------------------

DNA was sequenced using Sanger DNA sequencing (Taihe Biotechnology Co. Ltd. Beijing China). Sequencing primers were as follows: F 5′-ACGTGACTGGCCCTGCTATACC-3′, F2 5′-CAGGAAGCCTCCC-3′, and the sequencing results were analyzed by Chromas2.23 and DNAMAN8.0 software. After successful sequencing, we aligned the sequences with the reference sequences reported in the National Center for Biotechnology Information database ([<https://www.ncbi.nlm.nih.gov/gene/>]{.ul}).

Statistical Analysis {#S0002-S2006}
--------------------

Genotype frequency and allele frequency were calculated by direct counting, and the chi-squared test was used to assess the associations of allele, genotype, and haplotype with schizophrenia risk. The odds ratio (OR) and 95% confidence interval (CI) were calculated using SPSS 22.0 (IBM, Armonk, NY, USA). Haploview4.2 (Broad Institute, Cambridge, MA, USA) was used to analyze Hardy--Weinberg equilibrium and haplotype confirmation. Power analysis was performed with the PS program (Dupont & Plummer, 1998). In all statistical analyses, significance was set at p\<0.05. Bonferroni correction was performed for cases with several independent trials (*p*\<0.05/4 was statistically significant). Pairwise differences between genotypes \[AA vs AA, AA vs AA, AA vs AA (A being the risk factor)\] were used to determine an appropriate genetic model.[@CIT0018]

Results {#S0003}
=======

Allele and Genotype Analyses {#S0003-S2001}
----------------------------

Through the analysis of the sequencing results, we detected 16 SNPs (single nucleotide polymorphism; rs12965479, rs72978691, rs11662010, rs7242919, rs11151014, rs11151015, rs75008330, rs80131113, rs35061175, rs5372, rs13306374, rs5373, rs13306375, rs1385809035, rs142660460, and rs5374). The allele frequencies and genotype frequencies of the detected SNPs are listed in [Table 1](#T0001){ref-type="table"}.Table 1Genotype and Allele Frequencies of *GALR1* SNPs in Control Subjects and Schizophrenia PatientsSNPsCaseControl*P* valueOR95% CIN%N%**rs12965479**0.846 A/A32994.8127394.46 A/G185.19165.54 G/G00.0000.00 G Allele182.59162.770.8920.9350.356--2.456**rs72978691**0.261 C/C21261.1015854.67 A/C11432.8511038.06 A/A216.05217.27 A Allele15622.4815226.30.2630.8130.565--1.169**rs11662010**0.484 A/A21261.1016356.4 A/G11533.1410837.37 G/G205.76186.23 G Allele15522.3314424.910.4590.8710.603--1.256**rs7242919**0.100 C/C185.19165.54 C/G11332.5611740.48 G/G21662.2515654 G Allele54578.5342974.220.2011.2700.880--1.832**rs11151014**0.243 T/T21762.5516256.06 G/T11131.9911038.06 G/G195.48175.88 G Allele14921.4714424.910.3160.8280.572--1.198**rs11151015**0.193 A/A21963.1116256.06 A/G11031.7011038.06 G/G185.19175.88 G Allele14621.0414424.910.2460.8030.554--1.164**rs75008330**0.502 G/G29083.5724885.81 A/G5616.143913.49 A/A10.2920.69 A Allele588.36437.440.7211.1110.624--1.979**rs80131113**0.115 T/T28080.6924685.12 C/T6619.024013.84 C/C10.2931.04 C Allele689.80467.960.4191.2560.722--2.186**rs35061175**0.844 C/C32994.8127595.16 C/T185.19144.84 T/T00.0000 T Allele182.59142.420.8911.0730.395--2.917**rs5372**0.837 C/C6418.445519.03 C/G21361.3817159.17 G/G7020.176321.8 G Allele35351.8629751.380.9011.0200.747--1.394**rs13306374**0.330 A/A21762.5416456.75 A/C11332.5610837.37 C/C174.90175.88 C Allele14721.1814224.570.3220.8290.572--1.202**rs5373**0.948 C/C15845.5312844.29 C/G15945.8213647.06 G/G308.65258.65 G Allele21931.5618632.180.8780.9740.697--1.361**rs13306375**0.368 A/A20960.2315854.67 A/G12034.5811439.45 G/G185.19175.88 G Allele15622.4814825.610.3570.8420.585--1.214**rs1385809035**0.107 C/C30688.1826692.04 C/G4111.82237.96 G/G00.0000 G Allele415.91233.980.2811.4880.719--3.078**rs142660460**0.154 C/C32092.2225788.93 A/C277.783211.07 A/A00.0000 A Allele273.89325.540.3690.7150.343--1.491**rs5374**0.596 T/T15945.8313044.98 C/T15243.8013546.71 C/C3610.37248.3 C Allele22432.2818331.660.8821.0260.734--1.433[^1]

Among the 16 SNPs detected in the control group, the distributions of all of them with the exception of rs5372 were in Hardy--Weinberg equilibrium (*p*\>0.05, when the P value is more than 0.05, it indicates the genetic balance of the population; the data are from the same Mendelian population). The genotype and allele frequency distributions of the 16 SNPs did not differ significantly between the healthy population and schizophrenia patients (p\>0.05) ([Table 1](#T0001){ref-type="table"}).

Studies have shown that sex affects the correlation between candidate genes and the risk of schizophrenia.[@CIT0019] A subgroup analysis based on sex was thus performed here on the detected SNPs and their association with the risk of schizophrenia, the results of which are shown in [Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}. Among the females, allele A of rs72978691 (*p*=0.007), allele G of rs11662010 (*p*=0.032), allele G of rs11151014 (*p*=0.014), allele G of rs11151015 (*p*=0.019), allele C of rs13306374 (*p*=0.009), allele G of rs5373 (*p*=0.005), and allele G of rs13306375 (*p*=0.010) were identified as risk alleles for schizophrenia, while allele G of rs7242919 (*p*=0.007) was identified as a protective allele for schizophrenia in this study. To further explore which genotypes are associated with this condition, a model analysis of these eight SNPs was performed ([Table 4](#T0004){ref-type="table"}).Table 2Genotype and Allele Frequencies of *GALR1* SNPs in Control Male Subjects and Male Schizophrenia PatientsSNPsCaseControl*P* valueOR95% CIN=132%N=187%**rs12965479**0.843 A/A12594.7017895.19 A/G75.3094.81 G/G00.0000.00 G Allele72.6592.410.8451.1050.406--3.004**rs72978691**0.815 C/C8262.1211058.82 A/C4332.586534.76 A/A75.30126.42 A Allele5721.598923.800.5140.8820.604--1.286**rs11662010**0.671 A/A8463.6411159.36 A/G4332.586635.29 G/G53.79105.35 G Allele5320.088622.990.3790.8410.572--1.237**rs7242919**0.891 C/C53.7994.81 C/G4534.096534.76 G/G8262.1211360.43 G Allele20979.1729177.810.8871.0280.703--1.502**rs11151014**0.781 T/T8362.8811360.43 G/T4433.336434.22 G/G53.79105.35 G Allele5420.458422.460.7750.9450.641--1.393**rs11151015**0.907 A/A8362.8811662.03 A/G4433.336233.16 G/G53.7994.81 G Allele5420.548021.390.7030.9270.629--1.366**rs75008330**0.126 G/G12090.9115683.42 A/G118.333016.04 A/A10.7610.53 A Allele134.92328.560.0780.5540.285--1.076**rs80131113**0.057 T/T12090.9115683.42 C/T107.583016.04 C/C21.5210.53 C Allele145.30328.560.1180.5990.313--1.145**rs35061175**0.786 C/C12493.9417794.65 C/T86.06105.35 T/T00.0000.00 T Allele83.03102.670.7891.1380.443--2.922**rs5372**0.645 C/C2720.453920.86 C/G8463.6411159.36 G/G2115.913719.79 G Allele12647.7218548.470.6650.9330.681--1.279**rs13306374**0.677 A/A8665.1511360.43 A/C4131.066534.76 C/C53.7994.81 C Allele5119.328322.190.5260.8810.595--1.304**rs5373**0.139 C/C7355.308444.92 C/G5239.398645.99 G/G75.30179.09 G Allele6625.0012032.090.0520.7060.496--1.004**rs13306375**0.427 A/A8564.3911058.82 A/G4231.826735.83 G/G43.03105.35 G Allele5018.948723.260.190.7710.522--1.319**rs1385809035**0.088 C/C12594.7016789.30 C/G75.302010.70 G/G00.0000.00 G Allele72.65205.350.0960.4820.201--1.157**rs142660460**0.645 C/C12191.6717493.05 A/C118.33136.95 A/A00.0000.00 A Allele114.17133.480.6521.2070.532--2.738**rs5374**0.146 T/T7355.308847.06 C/T5239.397942.25 C/C75.302010.70 C Allele6625.0011931.820.0620.7140.502--1.017[^2] Table 3Genotype and Allele Frequencies of *GALR1* SNPs in Control Female Subjects and Female Schizophrenia PatientsSNPsCaseControl*P* valueOR95% CIN=157%N=160%**rs12965479**0.967 A/A14894.2715194.38 A/G95.7395.63 G/G00.0000.00 G Allele92.8792.810.9681.020.399--2.603**rs729786910.022 \*** C/C7648.4110263.75 A/C6742.684930.63 A/A148.9295.63 A Allele9530.256720.94**0.007\*\***1.6381.141--2.351**rs11662010**0.071 A/A7950.3210163.13 A/G6541.404930.63 G/G138.28106.25 G Allele9129.006921.56**0.032\***1.4841.034--2.130**rs72429190.008\*\*** C/C117.0195.63 C/G7245.864830.00 G/G7447.1310364.38 G Allele22070.0625479.38**0.007\*\***0.6080.423--0.874**rs111510140.030\*** T/T7950.3210465.00 G/T6642.044729.38 G/G127.6495.63 G Allele9028.666520.31**0.014\***1.5761.093--2.273**rs111510150.041\*** A/A7950.3210364.38 A/G6642.044830.00 G/G127.6495.63 G Allele9028.666620.63**0.019\***1.5461.074--2.227**rs75008330**0.553 G/G12881.5313483.75 A/G2817.832616.25 A/A10.6400.00 A Allele309.55268.130.5261.1940.689--2.070**rs80131113**0.465 T/T12680.2512477.50 C/T3019.113622.50 C/C10.6400.00 C Allele3210.193611.250.6670.8950.541--1.482**rs35061175**0.610 C/C15196.1815295.00 C/T63.8285.00 T/T00.0000.00 T Allele61.9182.500.6140.760.261--2.215**rs5372**0.299 C/C2817.832515.63 C/G8755.4110263.75 G/G4226.753320.63 G Allele17154.4616852.500.6211.0820.792--1.478**rs133063740.022\*** A/A7849.6810465.00 A/C6742.684830.00 C/C127.6485.00 C Allele9128.986420.00**0.009\*\***1.6321.131--2.355**rs5373**0.114 C/C5535.037446.25 C/G8453.507345.63 G/G1811.46138.13 G Allele12038.228927.81**0.005\*\***1.6051.150--2.242**rs133063750.022\*** A/A7346.509961.88 A/G7245.865333.13 G/G127.6485.00 G Allele9630.576921.56**0.010\*\***1.6021.119--2.293**rs1385809035**0.416 C/C14189.8113986.88 C/G1610.192113.13 G/G00.0000.00 G Allele165.10216.560.4310.7640.391--1.494**rs142660460**0.189 C/C13686.6214691.25 A/C2113.38148.75 A/A00.0000.00 A Allele216.69144.380.2021.5670.782--3.139**rs5374**0.289 T/T5736.317245.00 C/T8352.877345.63 C/C1710.83159.38 C Allele11737.2610332.190.1801.2510.902--1.736[^3] Table 4The Model Analysis of Eight SNPs in FemalesSNPsModel*P* valueOR95% CIPowerrs72978691AAvsCC0.0992.0880.859--5.076C\>AAAVSAC0.7821.1380.456--2.840AA+ACvsCC**0.006\*\***1.8741.196--2.9370.780AAvsAC+CC0.2591.6430.690--3.913rs11662010GGvsAA0.2521.6620.693--3.989A\>GGGvsAG0.9650.9800.397--2.420GG+AGvsAA**0.021\***1.6901.079--2.6460.635GGvsAG+AA0.4861.3540.576--3.186rs7242919CCvsGG0.2591.7010.671--4.313C\>GCCvsCG0.6730.8150.314--2.115CC+CGvsGG**0.002\*\***2.0271.292--3.1800.861CCvsCG+GG0.6131.2640.509--3.140rs11151014GGvsTT0.2221.7550.705--4.371T\>GGGvsGT0.9140.9490.370--2.435GG+GTvsTT**0.008 \*\***1.8341.168--2.8790.735GGvsGT+TT0.4701.3890.568--3.394rs11151015GGvsAA0.2311.7380.698--4.330A\>GGGvsAG0.9140.9490.370--2.435GG+AGvsAA**0.002\*\***2.0131.291--3.1370.843GGvsAG+AA0.4701.3890.568--3.394rs13306374CCvsAA0.1432.0000.780--5.128A\>CCCvsAC0.8841.0750.408--2.830CC+ACvsAA**0.006\*\***1.8811.198--2.9530.788CCvsAC+AA0.3331.5720.625--3.958rs5373GGvsCC0.1211.8630.842--4.122C\>GGGvsGC0.6411.5960.553--2.623GG+GCvsCC**0.042\***1.5961.016--2.5070.490GGvsGC+CC0.3171.4640.692--3.100rs13306375GGvsAA0.1352.0340.791--5.230A\>GGGVSAG0.8401.1040.422--2.891GG+AGvsAA**0.006\*\***1.8681.194--2.9210.770GGvsAG+AA0.3331.5720.625--3.958[^4]

In the model analysis in females, these eight SNPs were all found different in the dominant model: AA+AC genotype of rs72978691 (*p*=0.006, OR=1.874, 95% CI=1.196--2.937, power=0.780), GG+AG genotype of rs11662010 (*p*=0.021, OR=1.690, 95% CI =1.079--2.646, power=0.635), CC+CG genotype of rs7242919 (*p*=0.002, OR=2.027, 95% CI =1.292--3.180, power=0.861), GG+GT genotype of rs11151014 (*p*=0.008, OR=1.834, 95% CI =1.168--2.879, power=0.735), GG+AG genotype of rs11151015 (*p*=0.002, OR=2.013, 95% CI =1.291--3.137, power=0.843), CC+AC genotype of rs13306374 (*p*=0.006, OR=1.881, 95% CI=1.198--2.953, power=0.788), GG+GC genotype of rs5373 (*p*=0.042, OR=1.596, 95% CI=1.016--2.507, power=0.490), and GG+AG genotype of rs13306375 (*p*=0.006, OR=1.868, 95% CI=1.194--2.921, power=0.770) were risk genotypes for schizophrenia. Bonferroni correction was performed to overcome the problem of multiple comparisons. The finding of significant associations of rs11662010 and rs5373 with the risk of schizophrenia was lost after Bonferroni correction. However, the associations of rs72978691, rs7242919, rs11151014, rs11151015, rs13306374, and rs13306375 with the risk of schizophrenia were still maintained at significant levels ([Table 4](#T0004){ref-type="table"}).

Linkage Disequilibrium and Haplotypes {#S0003-S2002}
-------------------------------------

In linkage disequilibrium analysis, rs72978691, rs11662010, rs7242919, rs11151014, and rs11151015 were shown to be strongly linked together (any two SNPs, D′\> 0.96, r^2^ \> 0.89) ([Figure 1](#F0001){ref-type="fig"}). In the control group, among the 16 SNPs, there were a total of 63 different haplotypes. Eight of these haplotypes (frequency \> 1%; [Table 5](#T0005){ref-type="table"}) were analyzed. It was found that H3 was associated with the risk of schizophrenia (*p*=0.011, OR=1.430, 95% CI=1.084--1.886), while H4 and H7 were protective against it (*p*=0.024, OR=0.526, 95% CI=0.298--0.927; *p*=0.037, OR=0.197, 95% CI=0.044--0.885, respectively) ([Table 6](#T0006){ref-type="table"}).Table 5Haplotypes of 16 SNPs in the *GALR1* Gene in Control SubjectsHaplotypers12965479rs72978691rs11662010rs7242919rs11151014rs11151015rs75008330rs80131113rs35061175rs5372rs13306374rs5373rs13306375rs1385809035rs142660460rs5374H1ACAGTAGTCCACACCTH2ACAGTAGTCGACACCTH3AAGCGGGTCGCGGCCCH4ACAGTAACCGAGACCCH5ACAGTAGTCCACACATH6GCAGTAGTTCACACCTH7ACAGTAGTCCACAGCTH8ACAGTAGCCGAGACCC[^5] Table 6Haplotype Analysis of *GALR1* SNPs in Control Subjects and Schizophrenia PatientsHaplotypeCase (n=578)Control (n=694)*P* valueOR95% CIN%N%H122238.426538.20.9351.0100.804--1.267H210317.812618.20.8770.9780.733--1.303H313222.811917.1**0.011\***1.4301.084--1.886H4183.1405.8**0.024\***0.5260.298--0.927H5315.4223.20.0511.7310.991--3.024H6111.9131.90.9691.0160.452--2.286H720.4121.7**0.037\***0.1970.044--0.885H820.491.30.1290.2640.057--1.228[^6] Figure 1Linkage disequilibrium block composed of rs12965479, rs72978691, rs11662010, rs7242919, rs11151014, rs11151015, rs75008330, rs80131113, rs35061175, rs5372, rs13306374, rs5373, rs13306375, rs1385809035, rs142660460, and rs5374. The number is the value of multiallelic *D*′ (**A**) and r^2^ (**B**), which represents the level of recombination between the two blocks.

In the female group, the eight SNPs rs72978691, rs11662010, rs7242919, rs11151014, rs11151015, rs13306374, rs5373, and rs13306375 were observed to be associated with the risk of schizophrenia, so they were then subjected to haplotype analysis in females. In the control group, there were a total of 17 different haplotypes consisting of the eight above-mentioned SNPs. We chose four haplotypes (frequency \> 1%; [Table 7](#T0007){ref-type="table"}) to analyze associations with the risk of schizophrenia, the results of which are shown in [Table 8](#T0008){ref-type="table"}. Among them, our findings suggested that FH2 may be correlated with the occurrence of schizophrenia (*p*=0.024, OR=1.858, 95% CI=1.080--3.196).Table 7Haplotypes of Eight SNPs in the *GALR1* Gene in the Female Control SubjectsHaplotypers72978691rs11662010rs7242919rs11151014rs11151015rs13306374rs5373rs13306375FH1CAGTAACAFH2AGCGGCGGFH3CAGTAAGAFH4CAGTACGG[^7] Table 8Haplotype Analysis of Eight *GALR1* SNPs in Female Control Subjects and Schizophrenia PatientsHaplotypeCase (n=314)Control (n=320)*P* valueOR95% CIN%N%FH119060.521366.70.1130.770.557--1.065FH28627.45416.8**0.001\*\***1.8581.266--2.727FH3216.7278.30.4950.7780.430--1.407FH410.372.20.0690.1430.017--1.168[^8]

Discussion {#S0004}
==========

In this study, the distribution of rs5374 in the control group did not conform to Hardy--Weinberg equilibrium, which may be related to the insufficiently random sampling, small population size, and presence of more than 16 SNPs in the analyzed fragment. The purpose of this study was to explore the correlation between the *GALR1* gene and the risk of schizophrenia in the Han Chinese.

In this study, H3 was identified as a risk haplotype of schizophrenia, while H4 and H7 were shown to be haplotypes protective against schizophrenia. The findings indicated that polymorphisms of the 5′ regulatory region of the *GALR1* gene are correlated with schizophrenia, and that the roles of haplotypes in this condition warrant further study. Although no clear mechanism has been found to date, reasonable biological evidence for this is available: GalR1 is mainly expressed in cortical areas associated with emotion and emotion control, and experiments have proven that GalR1 in the cerebral cortex is closely related to the occurrence of depression.[@CIT0020]

Moreover, numerous animal studies have shown that GalR1 is associated with depressive behavior.[@CIT0021]--[@CIT0027] In rodents, activation of GalR1 was shown to lead to depression-like behavior.[@CIT0027]--[@CIT0029] Many researchers have also reported that GAL mainly functions through GalR1--5-HT1A heteroreceptor complexes.[@CIT0030]--[@CIT0032] Furthermore, polymorphisms in GALR1 were reported to be associated with a variety of psychiatric disorders, such as rs5376 associated with heroin addiction, rs5374 associated with cocaine addiction, and rs5117162 associated with both of these addictions.[@CIT0016] Although to the best of our knowledge no research on the correlation between the *GALR1* gene and schizophrenia has been reported, many researchers have suggested that addiction, anxiety, depression, schizophrenia, and other psychiatric disorders might have similar genetic backgrounds.[@CIT0033],[@CIT0034] We thus proposed that *GALR1* may be correlated with schizophrenia. In the current studies, the hypothesis of dopamine and 5-HT was widely accepted. GalR1 inhibits the release of 5-HT, thus increasing the susceptibility to schizophrenia. Thus, *GALR1* may be one of the many pathogenic factors associated with schizophrenia.

Because the incidence of schizophrenia in females is significantly higher than that in males,[@CIT0035] in this study a subgroup analysis by sex was implemented. The results showed that, in the female group, rs72978691, rs7242919, rs11151014, rs11151015, rs13306374, and rs13306375 were significantly different between the schizophrenia group and the control group. No such difference was found in males. SNP is a bimodal magnetic marker with low heterozygosity. To improve heterozygosity and make more efficient use of genetic information, haplotype analysis was carried out on the female population in this study. Within the females, the haplotype FH2 was significantly different between the schizophrenia group and the control group and was identified as a risk factor for schizophrenia. It was thus indicated that there was indeed a correlation between the *GALR1* gene and schizophrenia, with this correlation being particularly strong in females. In terms of an explanation for this, it was previously reported that the GalR1 ligand GAL is closely related to estrogen production and release.[@CIT0020] In addition, the correlation between rs948854 and rs694066 of the GAL gene and depression was demonstrated only in females,[@CIT0012],[@CIT0020] although the mechanism behind this correlation needs to be confirmed by further studies. GalR1 is the main inhibitory receptor of GAL, so it is reasonable that there are also sex differences in the correlation between *GALR1* and schizophrenia.

There are some limitations of this study. First, there were not enough SNPs in the gene. Second, some deviation from HWE was identified. Third, a family-based study, which is more robust than a case--control design[@CIT0036] was not included in this work. Fourth, although interactions between multiple genes might affect the risk of schizophrenia, these were not studied here.[@CIT0037]

In conclusion, our study found an association between polymorphisms of the 5′ region of the *GALR1* gene and the risk of schizophrenia, especially in females. Additional larger studies on the etiology of schizophrenia are necessary, for which our data may provide a useful reference.
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[^1]: **Notes:** The SNPs with minor allele frequency \<0.01 were excluded. The *p*‐value was calculated by 2 × 3 and 2 × 2 chi‐squared test. The false discovery rate was \<0.05.

    **Abbreviations:** SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval; OR, odds ratio.

[^2]: **Notes:** The SNPs with minor allele frequency \<0.01 were excluded. The *p*-value was calculated by 2 × 3 and 2 × 2 chi-squared test. The false discovery rate was \<0.05.

    **Abbreviations:** SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval; OR, odds ratio.

[^3]: **Notes:** The SNPs with minor allele frequency \<0.01 were excluded. The *p*‐value was calculated by 2 × 3 and 2 × 2 chi‐squared test. The false discovery rate was \<0.05. The bold text indicates p\<0.05. \*p\<0.05, \*\*p\<0.01.

[^4]: **Notes:** The *p*‐value was calculated by 2 × 3 and 2 × 2 chi‐squared test, in which the codominant model, the recessive model, and the allele model were corrected by Bonferroni correction and *p* \< 0.05/4 was considered statistically significant. The statistical power was considered to be sufficient to detect any significant difference at power \>0.8. The false discovery rate was \<0.05. The bold text indicates p\<0.05. \*p\<0.05, \*\*p\<0.01.

    **Abbreviation:** SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval; OR, odds ratio.

[^5]: **Note:** The eight haplotypes are those at a frequency \>1% among the total of 63 haplotypes. Haplotypes with frequency \<1% were excluded.

    **Abbreviation:** SNP, single nucleotide polymorphism.

[^6]: **Notes:** The bold text indicates p\<0.05 \*p\<0.05.

    **Abbreviations:** SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval; OR, odds ratio.

[^7]: **Note:** The four haplotypes are those at a frequency of \>1% among the total of 17 haplotypes. Haplotypes with frequency \<1% were excluded.

    **Abbreviations:** SNP, single nucleotide polymorphism.

[^8]: **Notes:** The bold text indicates p\<0.05. \*\*p\<0.01.

    **Abbreviations:** SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval; OR, odds ratio.
